Stoke Therapeutics Inc (NAS:STOK)
$ 13.05 -0.05 (-0.38%) Market Cap: 690.88 Mil Enterprise Value: 409.98 Mil PE Ratio: 0 PB Ratio: 2.81 GF Score: 40/100

Stoke Therapeutics Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 05:50PM GMT
Release Date Price: $9.24 (+4.64%)
Joe Thome
TD Cowen - Analyst

(inaudible) on our orphan epilepsies corporate panel today at the 43rd annual healthcare conference. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And I am joined by my colleagues, Brendan Smith and Athena Chin. And it is our pleasure to have with us today a great corporate panel. We have CSO of Marinus Pharmaceuticals, Alex Aimetti; CEO of Ovid, Jeremy Levin; Marcio Souza, CEO of Praxis; and Edward Kaye, CEO of Stoke Therapeutics. So thank you all for joining us.

Questions & Answers

Joe Thome;Alex Aimetti
TD Cowen - Analyst;Marinus Pharmaceuticals, Inc. - Chief Scientific

We're going to start the conversation with a few thematic questions and then dive into some company-specific round robin a little bit. So maybe just to start, when you're thinking about new indications to look at, maybe what are the most important clinical and regulatory considerations for developing drugs specifically for orphan epilepsies, and maybe, Alex, we can kick it off with you?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot